Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adial Pharmaceuticals ( (ADIL) ) has issued an update.
On March 20, 2025, Adial Pharmaceuticals entered into an employment agreement with Tony Goodman to serve as the Chief Operating Officer starting April 1, 2025, with a base salary of $300,000 and potential bonuses. Goodman has been acting as COO since January 2024 under a Master Services Agreement, which will terminate with the new employment agreement, providing stability and continuity in leadership for the company.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for addiction and related disorders.
YTD Price Performance: -31.70%
Average Trading Volume: 859,633
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.85M
For an in-depth examination of ADIL stock, go to TipRanks’ Stock Analysis page.